FDA expands approval of Sutent to reduce the risk of kidney cancer returning

FDA approves first adjuvant treatment for adult patients who are at a high risk of kidney cancer returning after a kidney has been removed.

Home | Copyright 2008-2024 FoodandDrugRecall.org